This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
by Zacks Equity Research
Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
by Zacks Equity Research
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
by Zacks Equity Research
Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
by Zacks Equity Research
Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
by Zacks Equity Research
Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncobiologics, Inc. (OTLK) delivered earnings and revenue surprises of -83.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Oncobiologics, Inc. (OTLK) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Oncobiologics, Inc. (OTLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Hottest Wall Street Stories: What's Up, What's Down
by Sweta Killa
Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.